(+)-VINCRISTINE
HER2 + Breast Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Small moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the HER2 + Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Abemaciclib Mario Negri Institute for Pharmacological Research | Phase 3 | B |
HLX87 Shanghai Henlius Biotech | Phase 2/3 | B |
hlx22 Shanghai Henlius Biotech | Phase 2/3 | B |
tqb2102 Henan Cancer Hospital | Phase 2 | CCC |
ELGEMTUMAB Novartis Pharmaceuticals | Phase 1 | CC |
View all 9 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →